PCI Biotech AS is a subsidiary of Photocure, established in 2000 to commercialise its proprietary photochemical internalisation technology (PCI). The PCI technology was developed to introduce therapeutic molecules in a biologically active form specifically into the diseased cells.

The product development targets the large and fast-growing drug delivery market. In the pharmaceutical business, there is a large demand for technologies that can improve the efficacy and selectivity of existing products. Moreover, new biomolecules such as proteins, oligonucleotides and genes, are dependant on effective and specific drug delivery systems to realise their full therapeutic potential.

PCI Biotech is developing a new and specific photosensitising substance to be used in the PCI technology.

For further information please access the PCI Biotech web site.